Table of contents
April 2004 Vol 3 No 4
In This Issue
p283 | doi:10.1038/nrd1376
Editorial: The seven habits of highly effective drug discoverers?
p285 | doi:10.1038/nrd1375
News and Analysis
News
Rat genome sequence reignites preclinical model debate
p287 | doi:10.1038/nrd1377
News
News
Another long leaderless period in store for FDA
p289 | doi:10.1038/nrd1378
Patent watch
Court reversal in favour of Pfizer
p290 | doi:10.1038/nrd1365
Patent watch
University of Rochester COX2 patent invalid
p290 | doi:10.1038/nrd1366
Patent watch
Canada may need to review drug patent laws
p290 | doi:10.1038/nrd1370
Patent Primer
Patentability in Europe
p291 | doi:10.1038/nrd1350
An Audience With
Mark C. Fishman
p292 | doi:10.1038/nrd1363
From the analyst's couch
The Fast Track effect
p293 | doi:10.1038/nrd1349
Fresh from the Pipeline
Tadalafil and vardenafil
p295 | doi:10.1038/nrd1362
Research Highlights
Cardiovascular disease: Intensive care
p297 | doi:10.1038/nrd1371
Cardiovascular disease: Ezetimibe explained?
p298 | doi:10.1038/nrd1367
Inflammation: Free radicals on trial for microbicide: not guilty?
p298 | doi:10.1038/nrd1369
Virtual screening: Gliding to success
p299 | doi:10.1038/nrd1364
In brief
Chemical genomics | Anticancer drugs | Drug delivery
p300 | doi:10.1038/nrd1368
Neurodegenerative diseases: Linking lipids to Alzheimer's
p300 | doi:10.1038/nrd1372
Reviews
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Michelle R. Arkin & James A. Wells
p301 | doi:10.1038/nrd1343
siRNAs: applications in functional genomics and potential as therapeutics
Yair Dorsett & Thomas Tuschl
p318 | doi:10.1038/nrd1345
Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention
Martin Braddock & Anthony Quinn
p330 | doi:10.1038/nrd1342
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome
Neil Ruderman & Marc Prentki
p340 | doi:10.1038/nrd1344
Perspectives
Opinion
Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
Bryan L. Roth, Douglas J. Sheffler & Wesley K. Kroeze
p353 | doi:10.1038/nrd1346
Opinion
Cutting the cost of drug development?
Michael D. Rawlins
p360 | doi:10.1038/nrd1347
Opinion
Gene patenting and medical research: a view from a pharmaceutical company
Mike Stott & Jill Valentine
p364 | doi:10.1038/nrd1348
Careers and Recruitment
Correspondence
Correspondence: Fast dissociation rates predict neither efficacy nor lack of side-effects
Bryan L. Roth, Wesley K. Kroeze & Douglas J. Sheffler
| doi:10.1038/nrd1346-c2
